Skip to main content

Advertisement

Table 4 Changes in the responders and non- responder following 24 weeks treatment

From: Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Variables Responder group (n = 23) Non-responder group (n = 6)
Baseline 24 weeks Baseline 24 weeks
Body weight (kg) 66.8 ± 16.3 67.3 ± 17.4 62.4 ± 14.8* 64.3 ± 15.9
Waist Circumference (cm) 97.6 ± 12.2 98.0 ± 12.1 84.6 ± 85** 85.9 ± 8.4
Total insulin dose (units/day) 71.3 ± 14.9 32.1 ± 14.0 59.8 ± 12.9 ** 54.5 ± 14.7##
HbA1c (%) 9.5 ± 1.2 7.8 ± 1.1 8.6 ± 1.3* 8.4 ± 1.1##
FBG (mmol/L) 12.0 ± 2.7 7.4 ± 1.4 9.8 ± 2.1* 9.2 ± 1.5##
P2BG (mmol/L) 16.7 ± 4.8 9.8 ± 2.4 16.3 ± 4.2 15.8 ± 4.2##
HMW adiponectin (ug/ml) 2.89 ± 1.54 5.79 ± 1.58 4.74 ± 1.46** 5.11 ± 1.52##
  1. Normally distributed data expressed as mean ± standard deviation and non-normally distributed data expressed as median or as numbers and percentages. Non-normally distributed data were logtransformed for use with parametric statistics. HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; HMW: high-molecular weight; Data are mean ± SD. *p < 0.05 and **P <0.01 for responder vs. non-responder at baseline; #p<0.05 and ##p<0.01 for absolute changes in responder vs. non-responder following 24 weeks glimepiride treatment.